Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator

Wan Namkung, Kyung Hwan Kim, Min Goo Lee

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background & Aims: The most common form of the disease-causing cystic fibrosis transmembrane conductance regulator mutation, ΔF508, leads to a misfolded protein that undergoes endoplasmic reticulum-associated degradation. Retrieval of misfolded protein from the cis-Golgi or pre-Golgi intermediate compartment is a critical factor in endoplasmic reticulum retention and degradation of ΔF508 protein. Therefore, the inhibition of retrograde Golgi-to-endoplasmic reticulum traffic by the alkalinization of Golgi lumen may permit functional ΔF508 protein to reach the cell surface. Methods: Functional and biochemical effects of alkaline treatment on misfolded cystic fibrosis transmembrane conductance regulator-induced defects were measured in CFPAC-1 cells, which endogenously express ΔF508 cystic fibrosis transmembrane conductance regulator, and in CHO cells, which heterologously express ΔF508 cystic fibrosis transmembrane conductance regulator. The animal survival rate and the functional expression of cystic fibrosis transmembrane conductance regulator proteins were analyzed in homozygous ΔF508 mice after chronic treatment with weak base NaHCO3. Results: In CFPAC-1 and CHO cells, intracellular alkalization by reducing carbon dioxide concentrations in a carbon dioxide incubation chamber or intra-Golgi alkalization by bafilomycin A1 treatment increased the membrane expression of ΔF508 protein and cystic fibrosis transmembrane conductance regulator-dependent anion transport. Notably, chronic administration of NaHCO3 increased the long-term survival of homozygous ΔF508 mice and induced the functional expression of cystic fibrosis transmembrane conductance regulator in the luminal membrane of intestinal epithelium. Conclusions: We found that base treatments correct misfolded cystic fibrosis transmembrane conductance regulator-induced defects in vitro and in vivo. These results imply that the alkalization of intracellular compartments, in particular, Golgi or pre-Golgi intermediate compartments, can be a potential therapeutic target for the loss-of-function type of conformational diseases.

Original languageEnglish
Pages (from-to)1979-1990
Number of pages12
JournalGastroenterology
Volume129
Issue number6
DOIs
Publication statusPublished - 2005 Jan 1

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
CHO Cells
Proteins
Carbon Dioxide
Endoplasmic Reticulum
Endoplasmic Reticulum-Associated Degradation
Membranes
Intestinal Mucosa
Proteolysis
Anions
Mutation

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

@article{c886f7b34e61471591af2dcdce7f5b64,
title = "Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator",
abstract = "Background & Aims: The most common form of the disease-causing cystic fibrosis transmembrane conductance regulator mutation, ΔF508, leads to a misfolded protein that undergoes endoplasmic reticulum-associated degradation. Retrieval of misfolded protein from the cis-Golgi or pre-Golgi intermediate compartment is a critical factor in endoplasmic reticulum retention and degradation of ΔF508 protein. Therefore, the inhibition of retrograde Golgi-to-endoplasmic reticulum traffic by the alkalinization of Golgi lumen may permit functional ΔF508 protein to reach the cell surface. Methods: Functional and biochemical effects of alkaline treatment on misfolded cystic fibrosis transmembrane conductance regulator-induced defects were measured in CFPAC-1 cells, which endogenously express ΔF508 cystic fibrosis transmembrane conductance regulator, and in CHO cells, which heterologously express ΔF508 cystic fibrosis transmembrane conductance regulator. The animal survival rate and the functional expression of cystic fibrosis transmembrane conductance regulator proteins were analyzed in homozygous ΔF508 mice after chronic treatment with weak base NaHCO3. Results: In CFPAC-1 and CHO cells, intracellular alkalization by reducing carbon dioxide concentrations in a carbon dioxide incubation chamber or intra-Golgi alkalization by bafilomycin A1 treatment increased the membrane expression of ΔF508 protein and cystic fibrosis transmembrane conductance regulator-dependent anion transport. Notably, chronic administration of NaHCO3 increased the long-term survival of homozygous ΔF508 mice and induced the functional expression of cystic fibrosis transmembrane conductance regulator in the luminal membrane of intestinal epithelium. Conclusions: We found that base treatments correct misfolded cystic fibrosis transmembrane conductance regulator-induced defects in vitro and in vivo. These results imply that the alkalization of intracellular compartments, in particular, Golgi or pre-Golgi intermediate compartments, can be a potential therapeutic target for the loss-of-function type of conformational diseases.",
author = "Wan Namkung and Kim, {Kyung Hwan} and Lee, {Min Goo}",
year = "2005",
month = "1",
day = "1",
doi = "10.1053/j.gastro.2005.08.049",
language = "English",
volume = "129",
pages = "1979--1990",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "6",

}

Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator. / Namkung, Wan; Kim, Kyung Hwan; Lee, Min Goo.

In: Gastroenterology, Vol. 129, No. 6, 01.01.2005, p. 1979-1990.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator

AU - Namkung, Wan

AU - Kim, Kyung Hwan

AU - Lee, Min Goo

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background & Aims: The most common form of the disease-causing cystic fibrosis transmembrane conductance regulator mutation, ΔF508, leads to a misfolded protein that undergoes endoplasmic reticulum-associated degradation. Retrieval of misfolded protein from the cis-Golgi or pre-Golgi intermediate compartment is a critical factor in endoplasmic reticulum retention and degradation of ΔF508 protein. Therefore, the inhibition of retrograde Golgi-to-endoplasmic reticulum traffic by the alkalinization of Golgi lumen may permit functional ΔF508 protein to reach the cell surface. Methods: Functional and biochemical effects of alkaline treatment on misfolded cystic fibrosis transmembrane conductance regulator-induced defects were measured in CFPAC-1 cells, which endogenously express ΔF508 cystic fibrosis transmembrane conductance regulator, and in CHO cells, which heterologously express ΔF508 cystic fibrosis transmembrane conductance regulator. The animal survival rate and the functional expression of cystic fibrosis transmembrane conductance regulator proteins were analyzed in homozygous ΔF508 mice after chronic treatment with weak base NaHCO3. Results: In CFPAC-1 and CHO cells, intracellular alkalization by reducing carbon dioxide concentrations in a carbon dioxide incubation chamber or intra-Golgi alkalization by bafilomycin A1 treatment increased the membrane expression of ΔF508 protein and cystic fibrosis transmembrane conductance regulator-dependent anion transport. Notably, chronic administration of NaHCO3 increased the long-term survival of homozygous ΔF508 mice and induced the functional expression of cystic fibrosis transmembrane conductance regulator in the luminal membrane of intestinal epithelium. Conclusions: We found that base treatments correct misfolded cystic fibrosis transmembrane conductance regulator-induced defects in vitro and in vivo. These results imply that the alkalization of intracellular compartments, in particular, Golgi or pre-Golgi intermediate compartments, can be a potential therapeutic target for the loss-of-function type of conformational diseases.

AB - Background & Aims: The most common form of the disease-causing cystic fibrosis transmembrane conductance regulator mutation, ΔF508, leads to a misfolded protein that undergoes endoplasmic reticulum-associated degradation. Retrieval of misfolded protein from the cis-Golgi or pre-Golgi intermediate compartment is a critical factor in endoplasmic reticulum retention and degradation of ΔF508 protein. Therefore, the inhibition of retrograde Golgi-to-endoplasmic reticulum traffic by the alkalinization of Golgi lumen may permit functional ΔF508 protein to reach the cell surface. Methods: Functional and biochemical effects of alkaline treatment on misfolded cystic fibrosis transmembrane conductance regulator-induced defects were measured in CFPAC-1 cells, which endogenously express ΔF508 cystic fibrosis transmembrane conductance regulator, and in CHO cells, which heterologously express ΔF508 cystic fibrosis transmembrane conductance regulator. The animal survival rate and the functional expression of cystic fibrosis transmembrane conductance regulator proteins were analyzed in homozygous ΔF508 mice after chronic treatment with weak base NaHCO3. Results: In CFPAC-1 and CHO cells, intracellular alkalization by reducing carbon dioxide concentrations in a carbon dioxide incubation chamber or intra-Golgi alkalization by bafilomycin A1 treatment increased the membrane expression of ΔF508 protein and cystic fibrosis transmembrane conductance regulator-dependent anion transport. Notably, chronic administration of NaHCO3 increased the long-term survival of homozygous ΔF508 mice and induced the functional expression of cystic fibrosis transmembrane conductance regulator in the luminal membrane of intestinal epithelium. Conclusions: We found that base treatments correct misfolded cystic fibrosis transmembrane conductance regulator-induced defects in vitro and in vivo. These results imply that the alkalization of intracellular compartments, in particular, Golgi or pre-Golgi intermediate compartments, can be a potential therapeutic target for the loss-of-function type of conformational diseases.

UR - http://www.scopus.com/inward/record.url?scp=28844466291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844466291&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2005.08.049

DO - 10.1053/j.gastro.2005.08.049

M3 - Article

C2 - 16344066

AN - SCOPUS:28844466291

VL - 129

SP - 1979

EP - 1990

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 6

ER -